Blogs
Welcome to Unibest's Blogs section! Here, you will find valuable insights and in-depth reports covering various topics related to drugs and diseases. Our blogs aim to provide an enhanced understanding of the clinical significance and breakthroughs your clients can make. Stay updated with the latest trends, technological advancements, and industry analyses as we dive deep into the world of pharmaceuticals, giving you the knowledge and resources you need to stay ahead of the competition.
  • Unibest Unveils Innovative 505(b)(2) Project for Semaglutide: UB104

    2025-04-16

    In the ever-evolving landscape of pharmaceutical innovation, Unibest is proud to announce a groundbreaking development in the administration of Semaglutide, codenamed UB-PEP-104. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 14 2025

    2025-04-14

    This week, there are 6 drugs in the patent and exclusivity list. They are: - ONYX PHARMACEUTICALS INC A WHOLLY OWNED SUB OF AMGEN INC's KYPROLIS, containing active ingredient CARFILZOMIB - JANSSEN PRODUCTS LP's SYMTUZA, containing active ingredient COBICISTAT; DARUNAVIR; EMTRICITABINE; TENOFOVIR ALAFENAMIDE FUMARATE - INCYTE CORP's PEMAZYRE, containing active ingredient PEMIGATINIB - SEAGEN INC's TUKYSA, containing active ingredient TUCATINIB - RIGEL PHARMACEUTICALS INC's TAVALISSE, containing active ingredient FOSTAMATINIB DISODIUM - ASTRAZENECA PHARMACEUTICALS LP's TAGRISSO, containing active ingredient OSIMERTINIB MESYLATE Read More
  • Drug Briefing: Capivasertib

    2025-04-08

    Query Drug:OlaparibQuery Time:2025-03-10 13:13:19*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of April 07 2025

    2025-04-07

    This week, there are 9 drugs in the patent and exclusivity list. They are: - JANSSEN PHARMACEUTICALS INC's INVOKAMET, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKAMET XR, containing active ingredient CANAGLIFLOZIN; METFORMIN HYDROCHLORIDE - JANSSEN PHARMACEUTICALS INC's INVOKANA, containing active ingredient CANAGLIFLOZIN - ASTRAZENECA AB's BYDUREON BCISE, containing active ingredient EXENATIDE SYNTHETIC - ASTRAZENECA AB's FARXIGA, containing active ingredient DAPAGLIFLOZIN - BOEHRINGER INGELHEIM's GILOTRIF, containing active ingredient AFATINIB DIMALEATE - EISAI INC's DAYVIGO, containing active ingredient LEMBOREXANT - NOVARTIS PHARMACEUTICAL CORP's AFINITOR DISPERZ, containing active ingredient EVEROLIMUS - ASTRAZENECA PHARMACEUTICALS LP's KOSELUGO, containing active ingredient SELUMETINIB SULFATE Read More
  • Targeting c-Myc and a Molecular Glue: UB025

    2025-04-03

    The transcription factor c-Myc has emerged as a critical target in oncology, given its aberrant expression in more than 70% of human cancers. Unibest presents a first-in-class small molecule glue targeting c-Myc open for NewCo. Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 31 2025

    2025-03-31

    This week, there are 4 drugs in the patent and exclusivity list. They are: - ASTRAZENECA AB's WAINUA (AUTOINJECTOR), containing active ingredient EPLONTERSEN SODIUM - AZURITY PHARMACEUTICALS INC's HORIZANT, containing active ingredient GABAPENTIN ENACARBIL - BIOXCEL THERAPEUTICS INC's IGALMI, containing active ingredient DEXMEDETOMIDINE HYDROCHLORIDE - PHARMAAND GMBH's RUBRACA, containing active ingredient RUCAPARIB CAMSYLATE Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 24 2025

    2025-03-24

    This week, there are 10 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - NALPROPION PHARMACEUTICALS LLC's CONTRAVE, containing active ingredient BUPROPION HYDROCHLORIDE; NALTREXONE HYDROCHLORIDE - WYETH PHARMACEUTICALS LLC's PROTONIX, containing active ingredient PANTOPRAZOLE SODIUM - PURDUE PHARMA LP's OXYCONTIN, containing active ingredient OXYCODONE HYDROCHLORIDE - UCB INC's FINTEPLA, containing active ingredient FENFLURAMINE HYDROCHLORIDE - BRISTOL MYERS SQUIBB CO's ZEPOSIA, containing active ingredient OZANIMOD HYDROCHLORIDE - VERITY PHARMACEUTICALS INC's TLANDO, containing active ingredient TESTOSTERONE UNDECANOATE - NOVO NORDISK INC's OZEMPIC, containing active ingredient SEMAGLUTIDE - VIIV HEALTHCARE CO's CABENUVA KIT, containing active ingredient CABOTEGRAVIR; RILPIVIRINE - VIIV HEALTHCARE CO's VOCABRIA, containing active ingredient CABOTEGRAVIR SODIUM Read More
  • Drug Patent & Exclusivity Expiration Report - Week of March 17 2025

    2025-03-17

    This week, there are 9 drugs in the patent and exclusivity list. They are: - COLLEGIUM PHARMACEUTICAL INC's XTAMPZA ER, containing active ingredient OXYCODONE - SANTARUS INC's GLUMETZA, containing active ingredient METFORMIN HYDROCHLORIDE - INCYTE CORP's OPZELURA, containing active ingredient RUXOLITINIB PHOSPHATE - INCYTE CORP's JAKAFI, containing active ingredient RUXOLITINIB PHOSPHATE - FRESENIUS KABI USA LLC's SMOFLIPID 20%, containing active ingredient FISH OIL; MEDIUM CHAIN TRIGLYCERIDES; OLIVE OIL; SOYBEAN OIL - NOVARTIS PHARMACEUTICALS CORP's TASIGNA, containing active ingredient NILOTINIB HYDROCHLORIDE - NOVEN PHARMACEUTICALS INC's XELSTRYM, containing active ingredient DEXTROAMPHETAMINE - NOBELPHARMA CO LTD's HYFTOR, containing active ingredient SIROLIMUS - NOVARTIS PHARMACEUTICALS CORP's LOCAMETZ, containing active ingredient GALLIUM GA-68 GOZETOTIDE Read More
  • Drug Briefing: Olaparib

    2025-03-10

    Query Drug:OlaparibQuery Time:2025-03-10 13:13:19*** Disclaimer *** The information provided here is sourced from resources such as Drugs.com, the Orange Book, etc., and is auto-generated by the Unibest Digital Center. The content is intended exclusively for pharmaceutical professionals. Read More
  • Total 15 pages  Go to Page
  • Go